moves to amend the bill on page 204, line 9, by rewriting that line to read:

"§ 108A-54.2. Procedures for changing medical-clinical coverage policy."; and

to amend the bill on page 204, lines 13-26, by rewriting the lines to read:

"(e) The Department shall provide coverage of a new prescription medication approved by the Food and Drug Administration (FDA) that becomes available to the public if (i) the manufacturer of that medication is enrolled in the Medicaid Drug Rebate Program and (ii) the medication is approved for the treatment of any of the following conditions, as defined by the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders:

(1) Bipolar disorders, hypomanic, manic, depressive, and mixed.
(2) Childhood and adolescent depression.
(3) Major depressive disorders, single episode or recurrent.
(4) Obsessive-compulsive disorders.
(5) Paranoid personality disorder and other psychotic disorders.
(6) Schizo-affective disorders, bipolar or depressive.
(7) Schizophrenia.

If the new prescription medication approved for the treatment of any of the preceding conditions is not manufactured by a manufacturer enrolled in the Medicaid Drug Rebate Program, then, no later than the end of the next calendar quarter following the date the new prescription medication became available to the public, the Department shall, in consultation with the Physician's Advisory Group, review and submit a proposed policy to the Preferred Drug List (PDL) Review Panel regarding the inclusion of the new prescription medication as either a preferred or non-preferred drug on the Department's PDL."; and
to amend the bill on page 204, line 32, by inserting the following at the end of the line:
"The PDL Policy Review Panel shall meet no less than once a quarter.".

1  
2  
3  

SIGNED
Amendment Sponsor

SIGNED
Committee Chair if Senate Committee Amendment

ADOPTED  FAILED  TABLED